A1 Refereed original research article in a scientific journal

Withdrawal from long-term use of zopiclone, zolpidem and temazepam may improve perceived sleep and quality of life in older adults with primary insomnia




AuthorsLähteenmäki R, Neuvonen PJ, Puustinen J, Vahlberg T, Partinen M, Räihä I, Kivelä SL

PublisherNordic Association for the Publication of BCPT (former Nordic Pharmacological Society). Published by John Wiley & Sons Ltd

Publication year2019

JournalBasic and Clinical Pharmacology and Toxicology

Article number13144

Volume124

Issue3

First page 330

Last page340

Number of pages11

ISSN1742-7835

DOIhttps://doi.org/10.1111/bcpt.13144

Web address https://doi.org/10.1111/bcpt.13144

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/38844874


Abstract


Abstract: Long-term use of benzodiazepine agonists is
widespread, although guidelines recommend short-term use. Only few controlled
studies have characterized the effect of discontinuation of their chronic use on
sleep and quality of life. We studied perceived sleep and quality of life in 92
older (age 55-91) outpatients with primary insomnia before and after withdrawal
from long-term use of zopiclone, zolpidem or temazepam (BZDA). BZDA was withdrawn during one
month, during which the participants received psychosocial support and blindly melatonin
or placebo. An extensive questionnaire was used to study perceived sleep and
quality of life before withdrawal (baseline), and 1 month and 6 months later. 89
participants completed the 6-month follow-up. As melatonin did not improve
withdrawal, all participants were pooled and then separated based on the
withdrawal results at 6 months (34 Withdrawers versus 55 Nonwithdrawers) for this
secondary analysis. At 6 months, the Withdrawers had significantly (p < 0.05) shorter sleep onset latency and less difficulty in initiating
sleep than at baseline and when compared to Nonwithdrawers. Compared to baseline, both Withdwavers and Nonwithdrawers
had at 6 months significantly (p <
0.05) less fatigue during the morning and daytime. Stress was alleviated more
in Withdrawers than in Nonwithdrawers (p
< 0.05). Satisfaction with life and expected health one year later improved (p < 0.05) in Withdrawers. In
conclusion, perceived sleep disturbances, day-time fatigue, and impaired
quality of life may resolve within 6 months of BZDA withdrawal. These results encourage withdrawal from
chronic use of benzodiazepine-type hypnotics, particularly in older subjects.






 




Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 14:38